Abstract: A nucleotide sequence encoding human serum amyloid A3 (SAA3), isolated, purified and characterized from human mammary epithelial cells is disclosed. Proteins encoded thereby and methods of use for the same are also disclosed.
Type:
Grant
Filed:
January 21, 2003
Date of Patent:
May 6, 2008
Assignee:
The Board of Regents of the University of Nebraska
Inventors:
Thomas L. McDonald, Marilynn A. Larson, Annika Weber
Abstract: Methods of inducing differentiation of mammalian bone marrow stromal cells into cells of multiple embryonic lineages by contacting marrow stromal cells with precursor differentiation-inducing compounds followed by contacting the partially differentiated precursor cells with specific cell type differentiation-inducing compounds. In one embodiment, the MSC derived precursor cell cultures comprise cells, at least some of which simultaneously express markers that are characteristic of endodermal and ectodermal cell types. In another embodiment, the differentiated cells are insulin-secreting pancreatic islet cells. Precursor differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine.
Type:
Grant
Filed:
April 7, 2004
Date of Patent:
April 29, 2008
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: The objects of the present invention is to provide a preventive method for the progress of neuropsychiatric disorders, a therapeutic agent for neuropsychiatric disorders, a screening method thereof, and a therapeutic method through the analysis of the mechanisms leading to neuropsychiatric disorders such as Nasu-Hakola diseases and the like. The non-human animal model of oligodendrocytes developmental disorders was generated by making the DAP12 gene function deficient on its chromosome. The DAP12 knockout mouse develops myelination disorders including hypomyelinosis in the brain, particularly in the frontal head and the thalamus, further leading to neuropsychiatric disorders such as Nasu-Hakola disease and the like with aging. The screening method for a therapeutic agent, the diagnostic method, and the therapeutic method, wherein the DAP12 knockout mouse developing these disorders are used, have been developed.
Abstract: The invention includes compositions and methods for depleting antigen presenting cells, or for impairing the biological function of antigen presenting cells, which compositions are useful for treatment of graft versus host disease and other immune diseases.
Type:
Grant
Filed:
May 11, 2000
Date of Patent:
October 30, 2007
Assignee:
Yale University
Inventors:
Warren D. Shlomchik, Mark Jay Shlomchik, Stephen G. Emerson
Abstract: Reagents useful in nucleic acid immunization techniques are described. More particularly, adjuvanted genetic vaccine compositions are described, as are methods of using those compositions for inducing an enhanced immune response against a selected antigen.
Type:
Grant
Filed:
November 3, 1999
Date of Patent:
May 29, 2007
Assignee:
Powderject Vaccines, Inc.
Inventors:
Joel R. Haynes, Georg Widera, James T. Fuller, Timothy Shipley, Deborah Fuller, Mary Wu
Abstract: This invention relates to humanized antibodies and antibody preparations produced from transgenic non-human animals. The non-human animals are genetically engineered to contain one or more humanized immunoglobulin loci which are capable of undergoing gene rearrangement and gene conversion in the transgenic non-human animals to produce diversified humanized immunoglobulins. The present invention further relates to novel sequences, recombination vectors and transgenic vectors useful for making these transgenic animals. The humanized antibodies of the present invention have minimal immunogenicity to humans and are appropriate for use in the therapeutic treatment of human subjects.
Type:
Grant
Filed:
August 3, 2001
Date of Patent:
October 31, 2006
Assignee:
Therapeutic Human Polyclonals, Inc.
Inventors:
Roland Buelow, Josef Platzer, Wim van Schooten, Jens-Ulrich Buelow
Abstract: Disclosed and claimed is the use of a liquid jet intradermal administration apparatus that administers a composition: without a needle; and in the epidermis, dermis and/or hypodermis, such as a Pigjet apparatus, for administering bovine vaccines or immunogenic compositions, especially bovine plasmid vaccines or immunogenic compositions. Accordingly, the invention involves bovine immunogenic or vaccine compositions in such an apparatus, and methods for vaccinating bovines or for inducing an immunogenic response in bovines employing such an apparatus, as well as the apparatus containing bovine immunogenic or vaccine compositions.
Type:
Grant
Filed:
February 15, 2002
Date of Patent:
October 12, 2004
Inventors:
Franciscus Antonius Maria Rijsewijk, Remco Siebren Schrijver, Johannes Theodorus Van Oirschot
Abstract: Transgenic mice that produce high levels of humanized antibodies are described. Targeted gene replacement exchanges constant regions of the mouse immunoglobulin heavy and light chain genes with human genes, either through conventional gene targeting, or by use of the bacteriophage-derived Cre-loxP recombination system. The transgenic animals undergo antibody affinity maturation, and a class switch from the native immunoglobulin to the humanized form.